HBW Market News: CHPA Petitions For CBD Reg, PEW Urges Stronger Supplement Oversight
AHPA releases guidance for tea and infusion products on regulatory and liability implications as a result of increasing Prop 65 lawsuits; CHPA files citizen petition urging FDA to act on a CBD pathway; PEW pushes for stronger supplement oversight; and more.
You may also be interested in...
US CBD Supplement Market Anxious For Lawful Use Proposal, And FDA Offers Cannabis Drug Research Guidance
Adding more cannabis-containing drugs to the three already approved in the US relies on research, but hundreds of supplements and other FDA-regulated non-drug products containing CBDs already are available under enforcement discretion by the agency.
The trade group’s petition is second on a regulation for CBD’s use in non-drug products submitted to FDA and largely tracks with CHPA’s November 2019 petition. Comments continue to reach the FDA after in March it reopened its docket about establishing a CBD regulation, but with little data the agency says is needed for its decision.
Dietary supplement trade groups reacted on 26 November – in CRN’s case with umbrage – to the US Food and Drug Administration’s latest barrage of cannabidiol (CBD)-themed warning letters and accompanying update to consumers regarding CBD safety.